# Combination of Dasatinib and Peg-Interferon Alpha 2b in First Line for Chronic Myeloid Leukemia in Chronic Phase

> **NCT01872442** · PHASE2 · COMPLETED · sponsor: **Poitiers University Hospital**

## Conditions studied

- Chronic Phase of Chronic Myeloid Leukemia

## Interventions

- **DRUG:** Dasatinib
- **DRUG:** Peg-Interferon alpha2b

## Key facts

- **NCT ID:** NCT01872442
- **Lead sponsor:** Poitiers University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-15
- **Primary completion:** 2018-10-31
- **Final completion:** 2018-10-31
- **Target enrollment:** — (—)
- **Last updated:** 2020-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01872442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01872442, "Combination of Dasatinib and Peg-Interferon Alpha 2b in First Line for Chronic Myeloid Leukemia in Chronic Phase". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01872442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*